The suppression of SIRT2 activity by fluvastatin sodium offers a new avenue for therapeutic intervention, highlighting SIRT2 as a pivotal regulator of tumor progression and presenting a novel strategy for the targeted treatment of pancreatic cancer. The gene discussed is SIRT2; the disease is pancreatic neoplasm.